STREAM: A European real-world data platform for Relapsed/Refractory Acute Myeloid Leukemia
Funded by Horizon Europe, the IMPACT-AML project is developing STREAM, an open platform designed to harmonise the registration and analysis of real-world clinical data in relapsed or refractory acute myeloid leukemia (R/R AML), supporting research collaboration and evidence generation across Europe.
IMPACT-AML is a European research project funded by Horizon Europe that aims to improve the diagnosis and treatment of R/R AML. As part of this mission, the project is developing STREAM, an open registry and data framework that enables structured, pseudonymised capture of patient information across participating centres. By standardising real-world data collection (including clinical, genetic, and treatment data), STREAM strengthens cross-border collaboration, facilitates identification of cohorts for research and trial readiness, and provides insights into disease progression, treatment response, and survival to support better-informed decisions in routine and personalised care.
STREAM is an open platform for the registration of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients, developed under the European Rare Blood Disorders Platform (ENROL), within the European Reference Network on Rare Hematological Diseases (ERN-EuroBloodNet).
As part of this mission, STREAM promotes harmonisation of biobanking and supports Measurable Residual Disease (MRD) standardisation efforts, facilitating collaboration across healthcare providers and research institutions. This contributes to a robust ecosystem that prioritises patient-focused research, inclusivity, and consistent data practices across countries.
Discover more about the IMPACT-AML project and STREAM here!